A 2-Year Randomized, Multicenter, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of Intravenous Zoledronic Acid 5 mg Administered Either Annually at Randomization and 12 Months, or Administered at Randomization Only in the Prevention of Bone Loss in Postmenopausal Women With Osteopenia.

Trial Profile

A 2-Year Randomized, Multicenter, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of Intravenous Zoledronic Acid 5 mg Administered Either Annually at Randomization and 12 Months, or Administered at Randomization Only in the Prevention of Bone Loss in Postmenopausal Women With Osteopenia.

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Sep 2016

At a glance

  • Drugs Zoledronic acid (Primary)
  • Indications Metabolic bone diseases; Osteoporosis
  • Focus Biomarker; Registrational; Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Nov 2009 Results published in Obstetrics and Gynecology 114: 999-1007, No 5.
    • 28 Jul 2009 Actual patient number (581) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top